Top Markets
#1 Black Phoenix Black Phoenix +355.52%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.17%
#4 Akedo Akedo +48.78%
#5 Acurast Acurast +29.95%
#6 BasedHype BasedHype +23.54%
#7 Cryptopia Cryptopia +21.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.11%
#9 Avantis Avantis +20.16%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.50%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Pathfinder Cell Therapy, Inc. Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy, Inc.

PFND
Rank in Stocks #40882
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in... Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$0.0001
Last synced: 2026-08-12
Market Cap
$66.72K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Pathfinder Cell Therapy, Inc. (PFND)

Category

Healthcare
P/E ratio for Pathfinder Cell Therapy, Inc. (PFND)
P/E ratio as of 2026 TTM: 0
According to Pathfinder Cell Therapy, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Pathfinder Cell Therapy, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.